Does Insurance Cover Zepbound? How to Check and How to Appeal

Probably not, and the odds got worse in 2026.

GoodRx tracks commercial formulary data from MMIT covering more than 190 million lives. As of July 2026, 60% of commercially insured people had no coverage for Zepbound, up from 51% a year earlier, leaving more than 114 million people with none, an increase of about 17 million in a year [1].

The rest of that 100% is the part people miss. Only 4% of commercially insured people had unrestricted coverage, down from 5%, and 37% had restricted coverage, down from 45% [1]. So of the minority who have any Zepbound coverage at all, roughly nine in ten face prior authorization, step therapy or both.

An earlier snapshot of the same GoodRx data, reported by NPR in April 2026, put the year-over-year loss at about 12 million people for Zepbound and 12 million for Wegovy [2]. GoodRx’s July 2026 update revises the Zepbound figure upward and shows Wegovy moving the other way, with 1.6 million people gaining some Wegovy coverage and 27 million still without it [1]. Treat the two as different vintages of the same tracker, not as competing claims.

None of that tells you about your plan. This guide is about finding that out and what to do if the answer is no. It is information, not medical advice.

Why is the answer so often no?

Three separate things have to line up before a pharmacy will fill Zepbound on your insurance, and any one of them can break the chain.

1. Your employer has to have bought the benefit. Most people’s drug coverage comes from an employer or union plan, and weight-management drugs are an optional add-on. Business Group on Health runs two separate surveys here and they use different samples, so their headline percentages do not line up. Its GLP-1-specific survey, fielded February to March 2026 among 105 member employers, found 67% covered GLP-1s for weight management, with only 72% of those saying they were likely to continue in 2027 and 10% saying they likely would not [3]. Its broader 2027 Employer Healthcare Strategy Survey, released in August 2026, found the share covering GLP-1s for weight management fell from 72% in 2025 to 60% in 2026, with 14% having eliminated coverage or planning to for 2027 [3]. Different denominators, same direction of travel: down. IFEBP’s 2026 survey of roughly 300 plans found 36% cover GLP-1s for both diabetes and weight loss, 60% for diabetes only, and 45% for other approved conditions such as sleep apnea, with GLP-1s rising from 6.9% of annual claims in 2023 to 11.4% in 2026 [4].

2. Your pharmacy benefit manager has to list the drug. Even inside a plan that covers the category, the PBM’s formulary decides which brand and which presentation.

3. You have to clear prior authorization. That is where the roughly nine-in-ten restriction rate bites.

Marketplace plans are a harder case still. An analysis of all 300 carriers offering 2026 Marketplace plans found only 26, about 8.7%, cover GLP-1s for obesity, in nine states, and all but four of those limit coverage to a BMI of 40 or above [5].

How to check your own plan in fifteen minutes

Do these in order. Do them before the prescription is written, because a prescription submitted under the wrong code generates an automatic denial you then have to unwind.

Step 1. Call the pharmacy benefits number on the back of your card. Not the medical number. Ask, in these words:

• “Is Zepbound on my formulary, and at what tier?”
• “Which presentation is covered, the single-dose pen, the vial, or the KwikPen?”
• “Does my plan cover weight-management medications at all, or is that carved out?”
• “What are the prior authorization criteria, and can you send them to me?”

That third question is the one people skip and it is the most important. If your employer excluded the category, no appeal about medical necessity will fix it, because the drug was never a covered benefit.

Step 2. Pull the actual formulary document. Log into your PBM’s member portal and find the drug list PDF for the current plan year. Search it for “Zepbound” and for “tirzepatide.” Note the tier and any codes: PA for prior authorization, QL for quantity limit, ST for step therapy, SP for specialty, E for excluded.

Step 3. Note the presentation. This matters more for Zepbound than for almost any other drug, because the three presentations are treated differently by nearly every payer. Insurance billing generally runs through the single-dose pen. The vial and the KwikPen are self-pay products in Lilly’s own channel. If your prescription says vial and your plan covers the pen, the claim will reject.

Step 4. Ask about the diagnosis code. Zepbound has two approved uses: chronic weight management, and moderate-to-severe obstructive sleep apnea in adults with obesity. Some plans that exclude the weight-management use will cover the OSA use. Which code applies to you is a clinical determination for your prescriber, not something to shop for.

Where the big three PBMs stand in 2026

These are the standard national templates. Your employer may have bought a different one, so treat these as the starting position rather than the answer.

CVS Caremark

Effective July 1, 2025, Caremark removed Zepbound from its standard, advanced control and value commercial template formularies and made Wegovy the preferred weight-management GLP-1 [6]. The change hit roughly a third of the lives Caremark manages. Truveta measured the result: 9.6% of patients on anti-obesity tirzepatide switched drugs in July 2025, more than a 16-fold increase over the earlier 2025 average, and 82.8% of switchers moved to anti-obesity semaglutide [7]. CVS said more than 95% of prescriptions filled by affected members after July 1 were for Wegovy.

Caremark kept a formulary exception route: a member who had already tried Wegovy and either had severe or intolerable side effects or did not achieve sufficient weight loss could have a prescriber request a case-by-case medical necessity review [6]. Massachusetts’ Group Insurance Commission noted that all existing Zepbound prior authorizations, including those approved for moderate-to-severe OSA, transitioned to Wegovy, and that all members regardless of indication had to try and fail Wegovy first [6].

That decision drew an ERISA class action, Larkin v. Caremark RX (S.D.N.Y., No. 1:25-cv-07307), filed September 3, 2025, alleging the removal was driven by a rebate agreement with Novo Nordisk rather than clinical merit [8]. On August 26, 2026 Judge Louis L. Stanton denied Caremark’s motion to compel arbitration, holding that the arbitration clause in the Caremark.com website terms did not reach disputes about plan rights and coverage denials [9]. He then granted Caremark’s motion to dismiss in part. The denial-of-benefits claim under the plan terms and the breach of fiduciary duty, duty of loyalty claim survived; the prohibited-transaction claim and the duty-of-care claim were dismissed [9]. Caremark calls the suit without merit. Nothing has been decided on the merits, and a ruling that a case may proceed is not a finding that the allegations are true.

Separately, on May 28, 2026 CVS Health announced Zepbound would return to its most common commercial formularies as an additional preferred weight-management option alongside Wegovy, at the same tier, effective October 1, 2026, for plan sponsors that elect weight-management coverage. Both Wegovy injection and Wegovy tablets keep preferred status, and members already on Wegovy continue uninterrupted. In the same announcement Caremark removed its new-to-market block on Foundayo (orforglipron), Lilly’s oral GLP-1, effective June 1, 2026.

Two cautions on that October date. It applies to CVS Caremark’s standard template formularies, and a plan sponsor has to have adopted the template and have bought weight-management coverage in the first place. As of this writing the change has not yet taken effect, so verify with your own plan before assuming it reaches you.

Express Scripts

The 2026 Express Scripts National Preferred Formulary lists ZEPBOUND PENS as covered [10]. The matching 2026 exclusions document is explicit about the other two presentations: in the Weight Loss row it excludes ZEPBOUND KWIKPENS and ZEPBOUND VIALS, and names liraglutide, Foundayo, Wegovy HD, Wegovy Pens, Wegovy Tablets and Zepbound Pens as the preferred alternatives [11]. Mounjaro does not appear in the exclusions document at all.

That split is worth sitting with. The two presentations Lilly sells cheaply for cash, the KwikPen and the vial, are the two Express Scripts will not bill. The presentation it does cover, the single-dose pen, is the expensive one. Anyone comparing “is the KwikPen cheaper?” needs to answer it twice, once for cash and once for insurance, because the answer flips.

Mounjaro remains covered for type 2 diabetes with prior authorization.

Express Scripts prints a warning on every one of these documents that matters more than the drug list itself: “Not all the medications listed are covered by all prescription plans; check your benefit materials.” The plan sponsor, usually your employer, decides whether weight-loss drugs are in the benefit at all.

Evernorth, the Cigna unit that owns Express Scripts, also runs two employer-elected cost caps. Its Patient Assurance Program caps member cost at no more than $25 for up to a month’s supply on participating products where the plan gives first-dollar coverage, applied automatically at the register. A separate program announced in May 2025 caps member out-of-pocket cost for Wegovy and Zepbound at $200 per month for participating employers. Both require your employer to have bought in.

Optum Rx

On the Optum Rx Premium formulary effective January 1, 2026, ZEPBOUND SUBCUTANEOUS SOLUTION AUTO INJECTOR is Tier 2 with prior authorization, quantity limits and a benefit-design flag, while ZEPBOUND SUBCUTANEOUS SOLUTION, the vial, is marked Tier E, excluded [12]. Wegovy is Tier 2 with prior authorization and quantity limits. Mounjaro is Tier 2 with prior authorization for type 2 diabetes.

Optum Rx runs two standard commercial lists, Premium and Select. Premium prints excluded products with a Tier E mark; Select may simply leave them out. So a drug missing from the Select booklet is not proof of coverage or of exclusion.

What prior authorization actually asks for

Criteria vary, but the common elements across Express Scripts and Optum Rx published criteria are:

• BMI of 30 or above, or 27 or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea or cardiovascular disease
• Documented participation in a structured weight-management program, often for at least six months
• A prior trial of an alternative weight-loss medication (phentermine, Contrave, Qsymia are commonly named) or a documented contraindication or intolerance
• Prescriber attestation that lifestyle modification has been inadequate
• Age 18 or older
• No concurrent GLP-1 — plans will not approve Zepbound alongside Ozempic, Mounjaro, Wegovy, Trulicity or similar

Some plans use stricter BMI thresholds of 35 or 40. NPR’s reporting on the GoodRx data noted that a BMI-of-40 requirement is a common restriction, well above the BMI of 30 that clinically defines obesity [2].

If the prescription is for the sleep apnea indication, expect a different checklist: a sleep study or validated home sleep apnea test with an apnea-hypopnea index consistent with moderate-to-severe OSA, recent enough to satisfy the plan, plus documented obesity and the OSA diagnosis code on the claim.

Approvals are often time-limited. Some plans reauthorize every six or twelve months and ask for documented weight loss to continue.

The appeal sequence

If you get a denial, the order matters. Skipping a step usually gets your appeal bounced back.

For commercial coverage:

1. Read the denial letter and find the deadline. They are often short, sometimes 60 or 180 days, and they are binding.
2. Fix the obvious first. A large share of denials are administrative: the wrong presentation on the prescription, a missing BMI, a missing diagnosis code, no documentation of a lifestyle program. Have the prescriber resubmit a corrected prior authorization before you escalate.
3. Request a formulary exception if the drug is excluded rather than merely restricted. This is a medical necessity review, and only the prescriber can initiate it with clinical documentation. Ask for the exception form, or have the prescriber submit by fax or electronic prior authorization.
4. Internal appeal. Attach a letter of medical necessity. Useful contents: the diagnosis and BMI, what you have already tried and what happened, any documented intolerance to the preferred alternative, and why the preferred alternative is not clinically appropriate for you.
5. External review. If the internal appeal fails, most plans must offer review by an independent third party. The denial letter must tell you how to request it.

For Medicare Part D: the sequence is a coverage determination, then a redetermination by the plan, then review by an independent review entity [13].

When an appeal will not help: if your employer excluded weight-management drugs from the benefit entirely, a medical necessity appeal generally cannot create a benefit that does not exist. In that case the realistic paths are a different genuinely applicable indication, raising it with HR at open enrollment, or paying cash.

The state-employee wrinkle

Public-sector plans have moved in both directions, which is a useful reminder that these decisions are budget decisions.

North Carolina ended State Health Plan coverage of GLP-1s for weight loss in April 2024, affecting a plan covering more than 750,000 people. At the cutoff about 23,000 members were using them at a net cost above $800 per member per month after rebates. An October 2025 agreement with CVS Caremark gave the plan the right to negotiate directly with manufacturers, and Treasurer Brad Briner asked for roughly $100 million to restore a narrower benefit. The budget signed in July 2026 did not include it. Diabetes coverage, including Mounjaro, continued throughout.

Colorado went the other way. Effective May 1, 2026, state employee plans restored weight-loss GLP-1 coverage under a GLP-1 Benefit 360 Program, but Cigna-plan members have access only to Zepbound for weight-loss indications unless there is a documented medical necessity for another drug [14]. That is the exact mirror image of what CVS Caremark did nationally in 2025.

If the answer stays no

Lilly’s self-pay channel does not require insurance and does not check income. Zepbound self-pay is $299 a month for 2.5 mg, $399 for 5 mg and $449 for 7.5 mg through 15 mg (verified 2026-09-14 on Lilly’s own coverage-and-savings pages), for the vial or the KwikPen, with the higher tier conditioned on refilling within 45 days [15].

If you have commercial insurance that simply does not cover Zepbound, Lilly’s savings card has a second tier that sets the single-dose pen at as low as $499 per month. For most people the self-pay route is cheaper.

Three caveats apply to every cash route. It cannot be combined with insurance on the same fill. Nothing you spend counts toward your deductible or out-of-pocket maximum. And the savings card programs exclude anyone on Medicare, Medicaid, Medigap, TRICARE, VA or DoD coverage, though those beneficiaries can still buy at self-pay prices outside their coverage.

A short checklist

• Call the pharmacy benefits number; ask about formulary status, presentation, category exclusion and PA criteria
• Download the current-year formulary PDF and search for “tirzepatide”
• Confirm the prescription names the presentation your plan actually covers
• Gather BMI, comorbidities, prior medication trials and lifestyle-program documentation before the PA goes in
• If denied, note the deadline, fix administrative errors, then escalate in order
• Re-check every fall; formularies reset January 1 and July 1

Sources

1. GoodRx, tracking insurance coverage for weight-loss medications: https://www.goodrx.com/healthcare-access/research/tracking-insurance-coverage-weight-loss-meds
2. NPR, restrictions on obesity drug coverage force patients to pivot: https://www.npr.org/2026/04/22/nx-s1-5794613/health-insurance-wegovy-zepbound
3. Business Group on Health, 2026 GLP-1 survey: https://www.businessgrouphealth.org/newsroom/news-and-press-releases/press-releases/2026-glp-1-survey
4. IFEBP, GLP-1 drugs survey report 2026: https://blog.ifebp.org/glp-1-drugs-survey-report-what-employers-are-and-arent-covering-in-2026/
5. Becker’s Payer Issues, GLP-1 coverage under ACA plans continues to decline: https://www.beckerspayer.com/payer/aca/glp-1-coverage-under-aca-plans-continues-to-decline-6-notes/
6. Massachusetts Group Insurance Commission, CVS Caremark decides to remove Zepbound from formulary: https://www.mass.gov/news/cvs-caremark-decides-to-remove-zepbound-from-cvs-caremark-formulary
7. Truveta Research, impact of the CVS GLP-1 formulary change: https://www.truveta.com/blog/research/research-insights/impact-of-the-cvs-glp-1-formulary-change-trends-in-switching/
8. Fierce Healthcare, CVS Caremark hit with class-action lawsuit over Zepbound: https://www.fiercehealthcare.com/payers/cvs-caremark-hit-class-action-lawsuit-over-decision-drop-zepbound-formulary
9. Bloomberg Law, CVS Caremark ordered to defend lawsuit over Zepbound coverage: https://news.bloomberglaw.com/employee-benefits/cvs-caremark-ordered-to-defend-lawsuit-over-zepbound-coverage
10. Express Scripts 2026 National Preferred Formulary: https://www.express-scripts.com/pdf/formulary/NPE1702_204612.pdf
11. Express Scripts 2026 National Preferred Formulary Exclusions: https://www.express-scripts.com/pdf/formulary/NPF_Preferred_Formulary_Exclusions2026.pdf
12. Optum Rx 2026 Premium formulary booklet: https://contenthub-aem.optumrx.com/content/dam/contenthub/onboarding/assets/wespath/Jan-01-2026-Premium-Formulary-Booklet.pdf
13. Medical Daily, denied coverage for Wegovy or Zepbound: https://www.medicaldaily.com/wegovy-zepbound-coverage-denial-appeals-value-assessment-2026-476427
14. Colorado Department of Personnel and Administration, GLP-1s for weight loss coverage change FAQ: https://dhr.colorado.gov/sites/dhr/files/documents/FAQs_%20GLP-1s%20for%20Weight%20Loss%20Coverage%20Change%202026.pdf
15. Eli Lilly, Zepbound savings and insurance options: https://zepbound.lilly.com/savings